Patient-recruitment specialist Synexus has won a place in Pfizer's stable of preferred providers, giving the company advance information about future clinical trials and a leg up on other outsourcers.
In yet another indication of the yawning gap between what drug developers know about Alzheimer's and how it could be treated, Eli Lilly today decided to scrap its Phase II study for a BACE inhibitor after gathering abnormal liver tests from patients.
GlaxoSmithKline has stopped development of an experimental drug for multiple sclerosis after a preclinical study turned out to contain "misrepresentations" in data from its R&D labs in China.
Efficacy results for an experimental rheumatoid arthritis drug in development by Eli Lilly and Incyte held up well as patients in a Phase IIb trial were tracked over the course of a full year.
Once again, Amgen's R&D chief Sean Harper has Roger Perlmutter to thank for a positive late-stage outcome on one of the Big Biotech's top cancer prospects.
The lung cancer vaccine race has brought together an unusual mix of players. Merck KGaA was in a good position, but its vaccine disappointed in Phase III, while GlaxoSmithKline could report data on its candidate this year. Then there is the Cuba-Argentina joint venture.
The head of GlaxoSmithKline's R&D operation in China has been fired while another researcher has resigned following a company probe into allegations that data on interleukin-7 research published in Nature Medicine was "misrepresented" by company researchers.
The FDA has lifted the clinical hold on PharmAthene's anthrax vaccine candidate, SparVax.
One of the patients enrolled in a mid-stage study for an experimental stem cell therapy from Pluristem Therapeutics suffered a severe allergic reaction, sending him to the hospital and prompting FDA officials to clamp a clinical hold on the study.
Sanofi's iniparib failed a Phase III study for squamous non-small cell lung cancer, the final strike against a once-promising drug that has proved a bitter disappointment for the pharma giant.